2026 Publications

Data Request IDLead InvestigatorInstitutionResearch Proposal TitlePublicationData Contributor(s)Altmetrics ScorePubMed Citation Total
4324Peng XieInstitute of Neuroscience, Chongqing Medical University Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: an individual patient data meta-analysisXiang, Yajie, Cuijpers, Pim, Li, Wei, Bao, Qingyan, Weisz, John R., Shi, Jie, Du, Xiaoyan, Yang, Hongmei, Barth, Jürgen, Coghill, David, Leucht, Stefan, Hazell, Philip, Cohen, David, Ravindran, Arun V., Michael, Kurt D., Teng, Teng, Zhou, Xinyu, Lu, Lin and Xie, Peng
""An Individual Participant Data Analysis: Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder"".
Journal of the American Academy of Child & Adolescent Psychiatryvol. , no. , May. 2026, pp.

doi:10.1001/jama.2026.1327
Lilly, GlaxoSmithKline, Pfizer Inc.
4917Andrea CiprianiUniversity of Oxford Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-AnalysisCipriani, Andrea, Fernandes, Karen Barros Parron, Mulsant, Benoit H., Efthimiou, Orestis, Williams, Nicola, Mort, Sam, Elgarf, Rania, Liu, Qiang, Haque, Nyla, Potts, Jennifer, Ede, Roger, Fox, Robin, Liboni, Marcos, Nesi Cavicchioli, Diego A., Simon, Judit, Smith, Katharine A., Zangani, Caroline, Li, Zhenpeng, Taylor, Ursula, Husain, M. Ishrat, Cipriani, Maddalena, Carpaneze Dalaqua, Paulo V., Leite, Eduardo Fernandes, Aliano Gâmbaro, Gustavo, Nabhan Silveira, Diogo, Manfredin Vila, Luísa, Liboni Cavicchioli, Fernanda, Furukawa, Toshi A., Naci, Huseyin, Ostinelli, Edoardo G., null, null, Adinda, Arradea Triesty, Ahmed, Nadeem, Aronica, Rosario, Batista, Eduarda, Benjamin, Jithen, Binnian, Ian, Carson, Ruth, Collins, Helen, Cook, Johanna, Delahay, Rachel, De Crescenzo, Franco, Engonidou, Lazarina, Gilbody, Simon, Hong, James, Hughes, Owen, Jaquiery, Matt, Johnston, Benjamin, Lewis, Gemma, Paggi, Andrea, Rizzopesci, Nicola, Sealy, Pippa, Shah, Neetul, Shaw, Rachel, Singh, Ilina, Stevens, Katherine, Tanna, Jaimini, Tomlinson, Anneka, Wainwright, Laurence, Wooding, Nick, Yu, Ly-Mee, Kloiber, Stefan, Mueller, Daniel, Kim, Helena K., Jones, Brett D.M., Ortiz, Abigail, Blumberger, Daniel, Salanti, Georgia, Araújo, Stéphanie P., Bignardi, Paulo R., Camargo, Bruna G., Colado Simões, Andréa N., de Vasconcelos, João Pedro, Fernandes, Bianca B. P., Gobbi, Isadora L., Haber, Rafael S. A., Jacovetti, Renato C., Liboni, Augusto B. , Martins, Caio C. S., Oliveira, Amanda P., Ramos, Giulia G. A., Rodrigues, Carolina B. N., Santos, Raul H. M., Silva, Letícia F. R., Tassi, Gabriela G. and Tomazini, Vitor F.
""A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder"".
JAMAvol. 335, no. 14, Apr. 2026, pp. 1219

doi: 10.100110.1001/jama.2026.1327
Lilly, GSK, Lundbeck
5921Paul SchulzUniversity of Texas Health Science Center Houston The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort studyHarris, Kristofer, Shyer, Madison, Wang, Dulin, He, Elizabeth, Cattani, Matias, Zhang, Catherine, Farrell, Christine M., Jiang, Xiaoqian, Kim, Yejin and Schulz, Paul E.
"The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study"".
The Journal of Prevention of Alzheimer's Diseasevol. 13, no. 3, Mar. 2026, pp. 100483

doi: 0.1016/j.tjpad.2026.100483
Lilly
6008David HsiehUniversity of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitorsGovindu, Saiabhiroop, Gowda, Prashanth, Muquith, Maishara, Espinoza, Magdalena and Hsiehchen, David "Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab". Journal for ImmunoTherapy of Cancervol. 14, no. 1, Jan. 2026, pp. e013727

doi: /10.1136/jitc-2025-013727
Roche
6739Rifaquat RahmanDana-Farber/Brigham and Women's Cancer Center (Dana-Farber Cancer Institute) Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma Rudra Gupta, Tulika, Polley, Mei-Yin C., Redd, Robert, Lee, Eudocia Q., Arrillaga-Romany, Isabel, Gilbert, Mark R., Tan, Yujue, Touat, Mehdi, Drappatz, Jan, Welch, Mary R., Galanis, Evanthia, Ahluwalia, Manmeet S., Colman, Howard, Nabors, L. Burt, Hepel, Jaroslaw, Elinzano, Heinrich, Schiff, David, Chukwueke, Ugonma N., Beroukhim, Rameen, Nayak, Lakshmi, McFaline-Figueroa, J. Ricardo, Batchelor, Tracy T., Kaley, Thomas J., Lu-Emerson, Christine, Mellinghoff, Ingo K., Bi, Wenya Linda, Arnaout, Omar, Peruzzi, Pier Paolo, Haas-Kogan, Daphne, Tanguturi, Shyam, Aizer, Ayal, Doherty, Lisa, Santagata, Sandro, Meredith, David M., Chiocca, E. Antonio, Reardon, David A., Ligon, Keith L., Weller, Michael, Mehta, Minesh P., Wen, Patrick Y., Trippa, Lorenzo and Rahman, Rifaquat
"Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data"".
Journal of Clinical Oncologyvol. , no. , May. 2026, pp.

doi:10.1200/JCO-25-01586
Roche, Project Data Sphere
7074Gregory LipUniversity of LiverpoolHistory of bleeding is associated with higher risk of cardiovascular outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase IIICorica, B, Romiti , G F, Proietti, M, Boriani, G, Olshansky, B, Chao , T F , Huisman, M V and Lip , G Y H "History of bleeding is associated with higher risk of cardiovascular outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase III". European Heart Journal 2025

doi:10.1093/eurheartj/ehaf784.735"a>
Boehringer Ingelheim
7384Ulrich MansmannDepartment for Medical Information Processing, Biometry, and Epidemiology; Ludwig-Maximilian’s University MünchenApplication of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical TrialsAl Tawil, Amani, Lauseker, Michael and Mansmann, Ulrich
"Estimating causal effects on quality of life under treatment discontinuation: the ALTA-1L trial"".
Journal of Clinical Epidemiologyvol. 193, no. , May. 2026, pp. 112189

doi:10.1016/j.jclinepi.2026.112189"
Takeda
1
7404Reena KhannaLawson Health Research InstituteA Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled TrialsKhanna, Reena, Son, Surim, Zou, Guangyong and Roshanov, Pavel S "Estimation of the Harvey Bradshaw Index from the Patient-Reported Outcome 2 in Crohn’s Disease: Results Based on a Large Scale Randomized Controlled Trial". Inflammatory Bowel Diseasesvol. 31, no. 8, Dec. 2024, pp. 2097-2105

doi: 10.1093/ibd/izae281
Takeda
2
7595Ashley HopkinsFlinders University Predicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 Li, Lee X, Shahnam, Adel, Kichenadasse, Ganessan, Murray, Lewis, Woodman, Richard, Abuhelwa, Ahmad Y, Modi, Natansh D, Rowland, Andrew, Hopkins, Ashley M and Sorich, Michael J
""Heterogeneous Treatment Effect of Immune Checkpoint inhibitors by Pre-treatment Prognosis in Randomised Controlled Trials"".
JNCI Cancer Spectrumvol. , no. , Jan. 2026, pp.

doi: 0.1093/jncics/pkaf127
Roche
7599Hwanhee HongDuke University Combining data sources to identify effect moderation for personalized mental health treatmentWang, Qiao and Hong, Hwanhee
"Bayesian Hierarchical Models With Calibrated Mixtures of g‐priors for Assessing Treatment Effect Moderation in Meta‐Analysis"".
Statistics in Medicinevol. 45, no. 8-9, Apr. 2026, pp.

doi:10.1002/sim.70510
Johnson & Johnson, Lundbeck, Takeda
0
7661Baocheng ChangChu Hsien-I Memorial Hospital, Tianjin Medical UniversityEffects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high riskJiang, Wenhui, Wang, Jingyu, Li, Jing, Li, Yongmei, Zhang, Yi, Xu, Jie, Zhang, Jinghang, Gao, Zhongai, Cheng, Jingli, Yang, Juhong and Chang, Baocheng
"Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial".
Frontiers in Endocrinologyvol. 17, no. , Mar. 2026, pp.

doi:10.3389/fendo.2026.1768816
Sanofi
7667Ashley HopkinsFlinders University Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours Chhetri, Rakchha, Modi, Natansh D, Menz, Bradley D, Cornelisse, Erik, Postma, David, Kuderer, Nicole M, Lyman, Gary H, Swain, Sandra M, Li, Lee X, Abuhelwa, Ahmad Y, McKinnon, Ross A, Vatandoust, Sina, Kichenadasse, Ganessan, Rowland, Andrew, Sorich, Michael J and Hopkins, Ashley M
"Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events"".
JNCI: Journal of the National Cancer Institutevol. , no. , Feb. 2026, pp.

doi: 10.1016/j.cgh.2025.12.020
AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Pfizer Inc., Roche, Sanofi, Takeda
0
7758Nahid SultanaUniversity of Sheffield Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) Sultana, Nahid
"Indirect Comparisons with Population Adjustment Methods using Single-arm Studies in Health Technology Assessment".
University of Sheffield UK, 2024

doi: 10.25934/PR00007758
GSK
7844Linong JiPeking University People's Hospital Risk stratification and responder identification using a baseline model and a dynamic risk prediction model for GLP-1RA and SGLT2i in T2DM: a machine learning facilitated posthoc analysis of CVOTs Huang, Qi, Zou, Xiantong, Boyko, Edward J, Lian, Zhouhui, Zhou, Xianghai, Han, Xueyao and Ji, Linong
"Dynamic surveillance of the cardiovascular risk and identification of treatment responders in type 2 diabetes using a machine learning–based model"".
European Journal of Preventive Cardiologyvol. , no. , Apr. 2026, pp.

doi: 10.1093/eurjpc/zwag196
GSK, BioLINCC, Johnson & Johnson
7849Igor StojkovPaul-Ehrlich-InstitutDeterminants of study design for vaccines against opportunistic bacterial infections: a proof-of-concept for data-driven, individual patient data (IPD) analyses.Stojkov, Igor, Marchioro, Linda, Bekeredjian-Ding, Isabelle and Hofner, Benjamin
"Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response". Scientific Reportsvol. 16, no. 1, Mar. 2026, pp.

doi: 10.1038/s41598-026-42375-5
Sanofi
7850Vipul JairathThe University of Western OntarioImpact of concomitant baseline medication, advanced age and racial differences on efficacy of biologics and small molecules for Inflammatory Bowel DiseaseAhuja, Dhruv, Choi, Jaeyoun, Zou, Guangyong, Goodwin, Shane W., Jairath, Vipul and Singh, Siddharth "Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials".
Digestive Diseases and Sciencesvol. , no. , Feb. 2026, pp.

doi:10.1007/s10620-026-09753-5
Takeda, Pfizer, AbbVie, Johnson & Johnson
8427Ahmad AbuhelwaUniversity of Sharjah Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma Abuhelwa, Ahmad Y., Almansour, Sara A, Al-Shamsi, Humaid O., Abuhelwa, Ziad, Alqudah, Mohammad A. Y., Bustanji, Yasser, Semreen, Mohammad H, Alzoubi, Karem H, Modi, Natansh D, McKinnon, Ross A, Sorich, Michael J. and Hopkins, Ashley M
""Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials"".
Scientific Reportsvol. 16, no. 1, Feb. 2026, pp.

doi: 0.1038/s41598-026-37464-4
Johnson & Johnson
0
8560Emily FoxStanford UniversityHybrid machine learning modeling of Insulin-Glucose dynamics for T1DJunyi Zou, Bob and Tian, Lu "Automatic and Structure-Aware Sparsification of Hybrid Neural ODEs with Application to Glucose Prediction". The Fourteenth International Conference on Learning Representations (ICLR 2026), Submission Number: 13562, 2026,

doi:10.25934/PR00008560
JaebN/AN/A
8591John ReynoldsUniversity of BirminghamPatterns of skin flare in patients with systemic lupus erythematosus
Peterknecht, Elizabeth, Branco, Marco and Reynolds, John A "Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data". Lupus Science & Medicinevol. 13, no. 1, Feb. 2026, pp. e001916

doi: 10.1136/lupus-2025-001916
AstraZeneca
8850Changsheng MaBeijing Anzhen HospitalThe impact of malnutrition on the Efficacy and Safety of empagliflozin for people with heart failureLi, W, Zeng, R U I and Du, X I N "The effect of malnutrition on the efficacy and safety of empagliflozin: a post hoc analysis of the EMPEROR-Reduced trial". European Heart Journalvol. 46, no. Supplement_1, Nov. 2025, pp.

doi:10.1093/eurheartj/ehaf784.956
Boehringer Ingelheim
8879Micaela MorettiniUniversità Poiltecnica delle Marche Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D Piersanti, Agnese, Göbl, Christian, Burattini, Laura, Tura, Andrea and Morettini, Micaela "PREDICTING HYPOGLYCEMIA RISK IN EXERCISE: A TREE-BASED ENSEMBLE LEARNING APPROACH USING CONTINUOUS GLUCOSE MONITORING DATA". ATTD Barcelona 2026-11–14 March and ATTD-ASIA 2025 Singapore-9–11 December, SO006 / #611, Page 89S, 2026,

doi: 10.1177/15209156251412178
Jaeb
8944Wesley KerrUniversity of PittsburghEvaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsyKerr, Wesley T., Kok, Neo, McFarlane, Katherine N., Reddy, Advith S., Biju, Lavanya, French, Jacqueline A. and Goldenholz, Daniel M. "L‐Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications". Epilepsiavol. , no., Dec. 2025, pp.

doi: 10.1002/epi.70080
GSK, Johnson & Johnson, UCB
8944Wesley KerrUniversity of Pittsburgh Evaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy Kerr, Wesley T., Reddy, Advith S., Kok, Neo, McFarlane, Katherine N., Biju, Lavanya and French, Jacqueline A.
"Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency".
Epilepsiavol. , no. , Mar. 2026, pp.

doi: 0.1002/epi.70189
GSK, Johnson & Johnson, UCB
1
9053Johanna Elin GehinOslo University HospitalPersonalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritisGehin, Johanna E., Klaasen, Rolf A., Kristianslund, Eirik K., Jyssum, Ingrid, Sexton, Joseph, Warren, David J., Aletaha, Daniel, Haavardsholm, Espen A., Goll, Guro L., Syversen, Silje W. and Bolstad, Nils
"The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial".
Therapeutic Drug Monitoringvol. , no. , Feb. 2026, pp.

doi: 10.1097/ftd.0000000000001440
UCB
0
9098Stéphane OudardAssitance Publique des Hôpitaux de Paris External validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel – A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials


doi: 10.1016/j.euo.2026.03.022
Sanofi
9229Andreas MeidHeidelberg University HospitalMAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer
Meid, Andreas D., Leiva-Escobar, Ignacio, Choi, Siak-Leng and Valente, Delphine "Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results". vol. , no. , Feb. 2026, pp.

doi: 10.64898/2026.01.30.26345218
Roche, Daiichi Sankyo, Inc
9253Jiajun YanMcMaster University Statistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials Yan, Jiajun, Humphries, Brittany, Che, Menglu, Pullenayegum, Eleanor, Lee, Shun Fu and Xie, Feng
""An Empirical Comparison of Statistical Methods for Estimating Treatment Effects on EQ-5D in Randomized Clinical Trials".
Value in Healthvol. , no. , May. 2026, pp.

doi: 10.1016/j.jval.2026.04.009
AbbVie, Biogen, Eli Lilly, Pfizer, Sanofi, Takeda
9350Lucy VivashMonash UniversityEvaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsyVivash, Lucy, Johns, Hannah, O′Brien, Terence J. and Churilov, Leonid "The Epilepsy‐Desirability of Outcome Ranking ( DOOR ) as a Multi‐Faceted Consumer‐Informed Outcome Measure for Epilepsy Clinical Trials". European Journal of Neurologyvol. 33, no. 2, Feb. 2026, pp.

doi:10.1111/ene.70531
UCB
9384Evyn PetersUniversity Of Saskatchewan Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder Peters, Evyn M., Quadri, Adetunji, Aziz, Saba and Balbuena, Lloyd
"Episode duration and severity as predictors of placebo response in major depressive disorder"".
Journal of Affective Disordersvol. , no. , May. 2026, pp. 122014

doi: 10.1016/j.jad.2026.122014
Pfizer
9422James SalsburyUniversity of Sheffield Developing methodology for a delayed treatment effect present in a survival trial Salsbury, James
"Assurance Methods for Adaptive Clinical Trials with a Delayed Treatment Effect"".
White Rose eTheses Online UK, 2026

etheses.whiterose.ac.uk/id/eprint/38672/
Roche, Bristol Myers Squibb
9492David McAllister University of Glasgow Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions McChrystal, R. (2026, June 11). Attrition in randomised controlled trials: Patterns, determinants, and risk prediction using aggregate-level and participant-level trial data. Zenodo.

doi: 10.5281/zenodo.20645997
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB
9734James BrorsonThe University of Chicago Merging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks Brorson, James, Beniwal, Simmer, Giurcanu, Mihai, Landron, Danielle, Landron, Stacie, Siegler, James E., Prabhakaran, Shyam and Johnson, Julie A.
""Creation of a Merged Harmonized Large Database of Subject-Level Data from Acute Secondary Prevention Studies in Minor Non-Cardioembolic Stroke or TIA"".
Int J Cerebrovasc Dis Stroke 9: 205, 2026

doi: 10.29011/2688-8734.100205
AstraZeneca
9809Emma FrölingUniversitätsmedizin Charité Berlin, clinic for psychiatry and psychotherapySystematic Review and Meta-Analysis of Adverse Events During Levetiracetam TherapyFröling, Emma, Morales Sahm, Mariel, Schmude, Marcel, Assies, Charlotte P., Wittenberg, Michael, Rosenow, Felix, Bermpohl, Felix and Riemer, Thomas G.
"Reassessing the adverse event profiles of levetiracetam and brivaracetam: a systematic review and meta-analysis". Journal of Neurologyvol. 273, no. 3, Mar. 2026, pp.

doi:10.1007/s00415-026-13746-9
UCB
9863Yasuhiro HagiwaraThe University of TokyoDevelopment of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected PatientsHagiwara, Yasuhiro and Matsuyama, Yutaka "Statistical Efficiency of Model-Robust Direct Regression Adjustment in Randomized Clinical Trials with Binary Outcomes". Statistics in Biopharmaceutical Research, vol. , no. , Mar. 2026, pp. 1-33,

doi.org/10.1080/19466315.2026.2638477
GSK
9907Akihiro HirakawaTokyo Medical and Dental UniversitDeveloping new statistical methodology harnessing nonconcurrent control data in infectious disease platform trialsAsano, Junichi, Sato, Hiroyuki, Watanabe, Shin and Hirakawa, Akihiro "Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation". Statistics in Medicinevol. 45, no. 1-2, Jan. 2026, pp.

doi:10.1002/sim.70387
Lilly, Montreal Heart Institute, NIAID
9907Akihiro HirakawaTokyo Medical and Dental University Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials Watanabe, Shin, Shimizu, Yosuke, Sato, Hiroyuki, Uemura, Yukari and Hirakawa, Akihiro
"Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for COVID ‐19"".
Pharmaceutical Statisticsvol. 25, no. 3, May. 2026, pp.

doi: 10.1002/pst.70096
NIAID, Lilly, Montreal Heart Institute
9924Thomas BüttnerDepartment of Urology and Pediatric Urology, University Hospital BonnEvaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancerBüttner, Thomas, Klümper, Niklas, Ellinger, Jörg, Ritter, Manuel and Krausewitz, Philipp "Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival". JAMA Network Open, vol. 9, no. 3, Mar. 2026, pp. e260300,

doi.org/10.1001/jamanetworkopen.2026.0300
Takeda, Johnson & Johnson
9964João Sérgio NevesFaculdade de Medicina da Universidade do PortoEffects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetesNeves, J.S., Leite, A.R., Vale, C. et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia (2025).

Doi: 10.1007/s00125-025-06637-7
Lilly
10032Shenghong ZhangThe first affiliated hospital of Sun Yat-sen University Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis Tie, Y, Su, F, Zhang, J, Chen, M, Chen, R, Li, L and Zhang, S
"P0682 One-year Dynamics of Clinical Activity During Biologics Therapy in Patients of Ulcerative Colitis"".
Journal of Crohn’s and Colitisvol. 20, no. Supplement_1, Jan. 2026, pp.

doi: 10.1093
Takeda, Johnson & Johnson
10036Akihiro HirakawaTokyo Medical and Dental UniversityDevelopment of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's diseaseHanazawa, Ryoichi, Sato, Hiroyuki, Suzuki, Keisuke and Hirakawa, Akihiro "Applying a statistical model-based AI method to identify prognostic factors for long-term cognitive decline in Alzheimer’s disease: Evidence from pooled placebo data of four phase III trials".
International Journal of Medical Informaticsvol. 211, no. , May. 2026, pp. 106337

doi: 10.1016/j.ijmedinf.2026.106337
Lilly
10046Matthew GalskyIcahn School of Medicine at Mount Sinai Exploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer Tran, Michelle A., Cho, Byuri Angela, Izadmehr, Sudeh, Yoo, Seong-Keun, Youssef, Dina, Anker, Jonathan F., Farkas, Adam M., Figueiredo, Igor, Lee, Karen, Ananthanarayanan, Aparna, Balan, Sreekumar, Onkar, Sayali, Banchereau, Romain, Gupta, Saurabh, Chhibber, Aparna, Wang, Li, Beaumont, Kristin G., Li, Ziao, Garcia-Barros, Monica, Bicak, Mesude, Cordon-Cardo, Carlos, Brody, Rachel, Kim-Schulze, Seunghee, Yuen, Kobe, Mariathasan, Sanjeev, Atiq, Saad O., Adeyelu, Tolulope T., Elliott, Andrew, Barata, Pedro, McKay, Rana R., Gnjatic, Sacha, Gonzalez-Kozlova, Edgar, Mehrazin, Reza, Horowitz, Amir, Sfakianos, John P., Chowell, Diego, Galsky, Matthew D. and Bhardwaj, Nina
"A Tumor-Promoting Inflammatory SPP1 + Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer"".
Cancer Discoveryvol. , no. , Apr. 2026, pp. OF1-OF26

doi: 10.1158/2159-8290.cd-25-1774
Roche
0
10120Pablo BonangelinoUS Food and Drug AdministrationA Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatric patients
Das, Apu Chandra, Gwon, Yeongjin and Bonangelino, Pablo "Propensity Score-Based Borrowing-By-Parts Power Prior for Augmenting Control Arm in Clinical Trials: A Two-Stage Approach".
Statistics in Biosciencesvol. , no. , Jan. 2026, pp.

doi: 10.1007/s12561-026-09513-z
GSK
10158Si-Cong MaThe First Affiliated Hospital of Sun Yat-Sen University Biomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy Wang, Si-Heng, Gao, Ning, Wang, Yu-Ze, Huang, Jiamin, Gan, Zhen, Fang, Zengli, Wang, Zekang, Chen, Rui, Feng, Xianming, Pan, Baixu, Tan, Jinghong, Cai, Junchao, Li, Mengfeng, Yang, Weixiong, Cheng, Chao and Ma, Si-Cong
"Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC".npj Precision Oncologyvol. 10, no. 1, Mar. 2026, pp.

doi: 10.1038/s41698-026-01375-4
Roche
0
10450Sam RoystonReplica HealthMerging Big Datasets for Training Blood Glucose Prediction ModelsWolff, Miriam K., Royston, Sam, Fougner, Anders L., Schaathun, Hans Georg, Steinert, Martin and Volden, Rune "A perspective on harmonizing diabetes management datasets".
Data in Briefvol. 59, no. , Apr. 2025, pp. 111399

doi: 10.1016/j.dib.2025.111399
JAEB2
10499Stefan KoudstaalErasmus Medical Center Rotterdam, NL Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: the LIFE-Preserved Model Reitsma, Tessa H, Savarese, Gianluigi, Kuźma, Łukasz, Deo, Salil V, Pennells, Lisa, Hageman, Steven H J, Holtrop, Joris, Benson, Lina, Conrad, Nathalie, Lund, Lars H, Kurasz, Anna, Kaptoge, Stephen, Keene, Spencer J, Chilala, Chimweta, Pitt, Matilda, Fletcher, Robert A, Khunti, Kamlesh, Piepoli, Massimo, Rossello, Xavier, Lees, Jennifer S, Kavousi, Maryam, McEvoy, John William, Wood, Angela M, de Boer, Rudolf A, Andersson, Charlotte, Visseren, Frank L J, Koudstaal, Stefan, Di Angelantonio, Emanuele, Dorresteijn, Jannick A N, null, null, Angelantonio, Emanuele, Abreu, Ana, Visseren, Frank, Kavousi, Maryam, William McEvoy, John and Wood, Angela
"Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model"".
European Heart Journalvol. , no. , Mar. 2026, pp.

doi: 10.1093/eurheartj/ehag182
Boehringer Ingelheim
10783Kathryn ConnellyMonash University School of Clinical Sciences Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab Lin, Angela, Kandane-Rathnayake, Rangi, Morand, Eric F and Connelly, Kathryn
"Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data".
Lupus Science & Medicinevol. 13, no. 1, Jan. 2026, pp. e001928

doi: 10.1136/lupus-2025-001928
GSK
10842Youqi YangUniversity of Michigan Estimating the Effect of Tirzepatide on Body Weight in Specific Subgroups: A Secondary Analysis Across Trials Yang, Youqi, Dempsey, Walter and Mukherjee, Bhramar
"Data Integration for Estimating Subgroup-Specific Conditional Average Treatment Effects (CATEs) Using Coarsened External Information in Randomized Trials".
arXiv 2026

doi: 10.48550/arXiv.2604.20667
Lilly
11010João Pedro FerreiraFaculty of Medicine of Porto UniversitySerum magnesium and the effect of empagliflozin in heart failureFerreira, João Pedro, Zannad, Faiez, Butler, Javed, Filippatos, Gerasimos, Vasques-Nóvoa, Francisco, Marques, Pedro, Neves, João Sérgio, Anker, Stefan D and Packer, Milton "Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis". European Journal of Heart Failurevol. , no. , Feb. 2026, pp.

doi:10.1093/ejhf/xuag054
Boehringer Ingelheim
11010João Pedro FerreiraFaculty of Medicine of Porto University Serum magnesium and the effect of empagliflozin in heart failure Marques, Pedro, Vasques-Nóvoa, Francisco, Pintalhão, Mariana, Bergantim, Rui, Mendonça, Luís, Neves, João Sérgio, Friões, Fernando, Sharma, Abhinav, Filipatos, Gerassimos, Butler, Javed, Anker, Stefan, Zannad, Faiez, Packer, Milton and Ferreira, João Pedro
"Polycythemia, SGLT2 inhibitors, and associated outcomes across the cardio-kidney-metabolic spectrum: a pooled analysis of randomized trials".
European Journal of Internal Medicinevol. , no. , Jun. 2026, pp. 106989

doi: 10.1016/j.ejim.2026.106989
Boehringer Ingelheim, Johnson & Johnson
0
11162Morgan GramsNYU Grossman School of Medicine Global Study on How Chronic Kidney Disease Affects Cardiovascular Disease Risk Neuen, Brendon L., Major, Rupert W., Grams, Morgan E., Sang, Yingying, Coresh, Josef, Ballew, Shoshana H., Surapaneni, Aditya, de Pinho, Natalia Alencar, Arnlov, Johan, Arnott, Clare, Bell, Samira, Berry, Jarett, Brenner, Hermann, Ciemins, Elizabeth, Chang, Alexander R., Cushman, Mary, de Lemos, James A., Diaz-Tocados, Juan Miguel, Farjat, Alfredo E., Fletcher, Robert A., Gansevoort, Ron T., Heerspink, Hiddo J. L., Herrington, William G., Hong, Chuan, Horwitz, Edward J., Hwang, Shih-Jen, Jassal, Simerjot K., Kalra, Philip A., Katz, Ronit, Khan, Sadiya S., Kovesdy, Csaba P., Kronenberg, Florian, Lees, Jennifer S., Lloyd-Jones, Donald M., Mill, Jose Geraldo, Naimark, David M. J., Ndumele, Chiadi, Polkinghorne, Kevan R., Psaty, Bruce M., Schloemer, Patrick, Shlipak, Michael, Shrestha, Prabin, Song, Zean, Staplin, Natalie, Steubl, Dominik, Vart, Priya, Visseren, Frank L. J., Woodward, Mark, Yamagishi, Kazumasa, Young, Bessie A., Sabanayagam, Charumathi and Valdivielso, Jose M.
"Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals"".
Nature Medicinevol. , no. , May. 2026, pp.

doi: 10.1038/s41591-026-04437-z
Boehringer Ingelheim
11350Neeraj NarulaHamilton Health SciencesModified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) Thresholds as Predictors of Delayed Clinical Response to Upadacitinib in Patients with Crohn’s DiseaseWong, Emily C.L., Dulai, Parambir S., Marshall, John K., Jairath, Vipul, Reinisch, Walter and Narula, Neeraj "Week 12 Reduction in Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease is Predictive of Delayed Response to Upadacitinib in Crohn’s Disease". Clinical Gastroenterology and Hepatologyvol. , no. , Dec. 2025, pp.

doi: 10.1016/j.cgh.2025.12.020
AbbVie
0